Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
Allergan Aesthetics, an ABBVie company and Soliton today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONIC TM its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration 510 clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The acquisition of Soliton expands and complements Allergan …
– Allergan Aesthetics, an ABBVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONIC TM its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The acquisition of Soliton expands and complements Allergan Aesthetics’ Body Contouring treatment